James Harding, MD
Hematology & Oncology · New York, NYNPI 1306003793
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $92,038 of the $125,447 with a category attached, or 73.4%. 16 manufacturers reported payments, led by Jazz Pharmaceuticals Inc. at 31.6% of the total. 2025 is the largest year on record at $35,148, 5.7 times the $6,157 reported in 2019. Among hematology & oncology clinicians in NY with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 105 payments — averaging $1194.73 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Jazz Pharmaceuticals Inc.$40K
- E.r. Squibb & Sons, L.L.C.$21K
- AstraZeneca$18K
- Exelixis Inc.$10K
- Boehringer Ingelheim International GmbH$8K
- Merck$7K
- plus $22K from 10 others
Across 575 payments — averaging $10,321 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Eli Lilly$1.8M
- E.r. Squibb & Sons, L.L.C.$950K
- AbbVie$788K
- Incyte Corporation$675K
- Boehringer Ingelheim$590K
- AstraZeneca$496K
- plus $632K from 4 others
What the payments were for
- Consulting fees$92,03873%
- Speaking & faculty fees$18,74415%
- Travel & lodging$13,00510%
- Food & beverage$1,6491%
- Education$110%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Jazz Pharmaceuticals Inc. | 25 | $39,606 |
| E.r. Squibb & Sons, L.L.C. | 11 | $20,854 |
| AstraZeneca | 12 | $17,873 |
| Exelixis Inc. | 10 | $10,406 |
| Boehringer Ingelheim International GmbH | 10 | $8,259 |
| Merck | 12 | $6,573 |
| Astrazeneca UK Limited | 3 | $5,198 |
| AbbVie | 4 | $3,820 |
| Servier Bioinnovation | 3 | $3,790 |
| Amgen | 1 | $2,744 |
| Eli Lilly | 6 | $2,445 |
| Eisai Inc. | 1 | $2,400 |
| Boehringer Ingelheim Pharma GmbH & Co.kg | 2 | $1,144 |
| Puma Biotechnology, Inc. | 2 | $175 |
| Astrazeneca AB | 2 | $120 |
| Innovation Technologies Inc | 1 | $41 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$125,447 in reported general payments places this provider in the 90th percentile of 967 hematology & oncology providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| LenvimaLenvatinib Mesylate | 51 | $1,207,972 |
| PemazyrePemigatinib | 23 | $448,632 |
| CabometyxCabozantinib S-Malate | 21 | $357,329 |
| XareltoRivaroxaban | 51 | $31,146 |
| CreonLipase/Protease/Amylase | 13 | $26,219 |
| Enoxaparin Sodium | 13 | $3,770 |
| Ursodiol | 28 | $2,538 |
| Pantoprazole Sodium | 50 | $539 |
| Ondansetron Hcl | 47 | $446 |
| Dexamethasone | 29 | $318 |
| Oxycodone Hcl | 29 | $233 |
| Spironolactone | 25 | $200 |
| Furosemide | 22 | $36 |
| Tramadol Hcl | 12 | $32 |
| Amlodipine Besylate | 21 | $31 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Eisai Inc.Lenvima | $2,400 | $1,207,97251 claims |
| Exelixis Inc.Cabometyx | $10,406 | $357,32921 claims |
| AbbVieCreon | $3,820 | $26,21913 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 967 hematology & oncology providers in New York.
Other hematology & oncology in New York
- Michael SchusterNew York$1.6M
- Charles SawyersNew York$1.6M
- Manuel Hidalgo-MedinaNew York$1.4M
- Ross LevineNew York$968K
- Joshua SabariNew York$761K
- Gail RobozNew York$738K
- Jeffrey LaurenceNew York$640K
- John AllanNew York$580K
- Ilan ShapiraNew York$475K
- John MascarenhasNew York$456K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.